( BARCELONA Spain--(BUSINESS WIRE)--May ...)Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures,Health

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Medtronic (NYSE:MDT) today presented new long-term data from the ENDEAVOR clinical trial program reinforcing the existing safety and efficacy profile of the Endeavor(R) drug-eluting coronary stent system. Four-year results from the 100-patient first-in-man ENDEAVOR I trial and three-year results from the nearly 1,200 patient ENDEAVOR II trial demonstrate that Endeavor is associated with sustained safety, significant reductions in repeat procedures and no late stent thrombosis in either trial using the pre-specified trial protocol definitions. The ENDEAVOR II study also showed that the Medtronic Driver(R) bare metal stent offers consistent and durable long-term clinical results.

The data was presented by Andreas Zeiher, M.D., J.W. Goethe-University, Frankfurt, Germany, during the EuroPCR's late-breaking clinical trial session. The Endeavor stent is approved in more than 100 countries worldwide and currently is under review by the U.S. Food and Drug Administration. FDA approval is anticipated in the second half of 2007.

The ENDEAVOR I data continue to show excellent long-term results, with only one clinical event between years three and four, a non-cardiac death from cancer. Target Lesion Revascularization (TLR) at four years was 3.1% and Target Vessel Revascularization (TVR) was 5.2%. The Major Adverse Cardiac Event (MACE) rate, one of the trial's primary endpoints, was 7.2%, with no late stent thrombosis events in this patient cohort.

Through three years of follow-up in the ENDEAVOR II trial, the TLR rate was 7.3%, compared to 14.7% for the Driver bare metal control arm (p= less than 0.001), representing a 50% reduction in the need for repeat procedures. Target Vessel Failure, the trial's primary endpoint, was 12.8% for Endeavor and 21.4% for Driver, a 40% reduction (p= less than 0.001). Endeavor showed a MACE rate of 12.0% at three years, compared
'"/>

Page: 1 2 3
Related medicine technology :

1. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
5. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
6. NCCN Updates Esophageal and Gastric Cancer Guidelines
7. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
8. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
9. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up